Life Sciences Tools and Services
Company Overview of Helomics Corporation
Helomics Corporation, a personalized healthcare company, develops and delivers a portfolio of products to guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. The company develops Precision Cellular Analytical Platform, a technology platform that collects and analyzes cell cycle and proliferation data for over a 25-35 day timeframe. Its products include ChemoFx, a treatment marker that helps improve patient outcomes by supporting physicians in the selection of effective treatments for their gynecologic cancer patients; BioSpeciFx, a group of clinically relevant and validated biomarker tests to evaluate a patient’s tumor at a molecular level an...
2516 Jane Street
Pittsburgh, PA 15203
Founded in 1995
Key Executives for Helomics Corporation
Chief Executive Officer, President and Director
Chief Financial Officer and Vice President
Vice President of Operations
Vice President of Human Capital
Compensation as of Fiscal Year 2016.
Helomics Corporation Key Developments
Helomics Corporation Wins Federal Supply Schedule Contract
Jun 9 16
Helomics Corporation announced that the National Acquisition Center of the Department of Veterans Affairs has awarded the company a Federal Supply Schedule (FSS) Contract V797D-506041, effective June 1, 2016 through May 31, 2021. The awarding of this contract will provide all government facilities, including those operated by the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD), easy access to Helomics™ ChemoFx® 3tumor profiling test. ChemoFx provides tumor-specific information to assist physicians in the identification of ineffective and effective chemotherapies for an individual patient's tumor. By determining the sensitivity of tumor cells to certain drugs, the test helps physicians identify the drugs most likely to impact the patient's tumor, sparing patients months of undergoing ineffective treatment and the costs associated with such treatment.
Helomics Announces Second Phase of Realignment Towards Research and Clinical Products Company in Personalized Healthcare
Apr 19 16
Helomics Corporation announced the start of a second phase of corporate realignment towards becoming an integrated clinical research and clinical products company. During this restructuring the laboratory operations at Helomics, including the processing of its ChemoFx, GeneFX, BioSpeciFx, CellFx and DEFENDER tumor profiling tests, will continue at full capacity. As part of this second realignment phase, Helomics will restructure its R&D, operations, and sales and marketing to refocus its efforts on the central buying and decision-making processes of Medicare, Commercial Payer’s and hospital systems. To reflect this realignment, a reduction-in-force was also completed, primarily sales professionals calling on individual oncologists. This strategic shift was brought on primarily by changes resulting from the Affordable Care Act (ACA), which have made cost the sole driver for healthcare decision-making, to the determent of new technologies and diagnostics in the personalized medicine arena. Due to this, the decision-making process for the utilization of new technologies has shifted into a more centralized process. In parallel, Helomics is forming a new research products division that will focus on the pharmaceutical, biotech and clinical research sectors. The company’s clinical products business will also be restructured into a new division focused on advanced lab developed tests (ALDT) and preparation for products in the FDA diagnostics markets as the regulatory oversight begins to shift in the personalized medicine marketplace.
Helomics Corporation Launches Genefx Colon to Identify Patients with High Risk Stage II Colon Cancer
Mar 15 16
Helomics Corporation announced the launch of GeneFx Colon, a prognostic multi-gene expression assay designed to identify colon cancer patients who are likely to experience recurrence within five years following initial surgery. GeneFx Colon is designed to enable physicians to make informed personalized treatment decisions about potentially adding adjuvant chemotherapy. GeneFx Colon is a proprietary gene signature test utilizing an individual patient’s RNA expression and a complex proprietary algorithm. GeneFx Colon is performed on a small amount of tumor tissue, which is removed during surgery or a biopsy, with results available within the average time period for recovery post-surgery. The lab analysis produces a binary test result that categorizes patients as being at either high or low risk of having a tumor recurrence within five years of surgery. Along with the clinical and pathological assessments, GeneFx Colon provides a clear result for risk of recurrence that can help guide physicians with decisions regarding the use of adjuvant therapy in patients with colon cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|